AsherBio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$55M
- Investors
-
17
AsherBio General Information
Description
Developer of immunotherapy drugs designed to treat cancer effectively. The company's drugs ramp up the immune system to take on cancer cells with precision with minimal side effects, enabling doctors to treat patients in a short period.
Contact Information
Website
www.asherbio.comCorporate Office
- 650 Gateway Boulevard
- Suite 100
- South San Francisco, CA 94080
- United States
Corporate Office
- 650 Gateway Boulevard
- Suite 100
- South San Francisco, CA 94080
- United States
AsherBio Timeline
AsherBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 16-Apr-2024 | $55M | Completed | Generating Revenue | ||
| 5. Debt - General | 15-Nov-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series B) | 01-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 23-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 05-Sep-2019 | $490K | $490K | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 21-Aug-2019 | $150K | Completed | Clinical Trials - Phase 1 |
AsherBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 362,500 | $0.000010 | $0.8 | $0.8 | 1x | $0.8 | 0.19% | |
| Seed-1 | 1,050,000 | $0.000010 | $0.14 | $0.14 | 1x | $0.14 | 0.55% |
AsherBio Comparisons
Industry
Financing
Details
AsherBio Competitors (55)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rakuten Medical | Venture Capital-Backed | San Diego, CA | ||||
| Intensity Therapeutics | Formerly PE-Backed | Westport, CT | ||||
| Linnaeus Therapeutics | Venture Capital-Backed | Haddonfield, NJ | ||||
| Cellerant Therapeutics | Venture Capital-Backed | Newark, CA | ||||
| Monopar Therapeutics | Formerly VC-backed | Wilmette, IL |
AsherBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AsherBio Patents
AsherBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230357343-A1 | Il-21 polypeptides and targeted constructs | Pending | 19-May-2021 | ||
| US-20230340104-A1 | Il-21 polypeptides and targeted constructs | Pending | 19-May-2021 | ||
| CA-3219181-A1 | Il-21 polypeptides and targeted constructs | Pending | 19-May-2021 | ||
| AU-2022275666-A1 | Il-21 polypeptides and targeted constructs | Pending | 19-May-2021 | ||
| EP-4340866-A1 | Il-21 polypeptides and targeted constructs | Pending | 19-May-2021 | C07K14/54 |
AsherBio Executive Team (7)
| Name | Title | Board Seat |
|---|---|---|
| Kyle Elrod | Chief Operating Officer | |
| Andy Yeung Ph.D | Co-Founder & Chief Technology Officer | |
| Ivana Djuretic Ph.D | Co-Founder, Chief Scientific Officer & Board Member | |
| Don O'Sullivan Ph.D | Chief Business Officer | |
| Craig Gibbs Ph.D | Chief Executive Officer & Board Member |
AsherBio Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Craig Gibbs Ph.D | Self | Chief Executive Officer & Board Member | |
| Elaine Sun | Self | Board Member | |
| Ian Clark | Self | Board Member | |
| Ivana Djuretic Ph.D | AsherBio | Co-Founder, Chief Scientific Officer & Board Member | |
| Jeffrey Tong Ph.D | Third Rock Ventures | Board Member |
AsherBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AsherBio Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AstraZeneca | Corporation | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| SNR | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Emles Venture Partners | Venture Capital | Minority |
AsherBio FAQs
-
When was AsherBio founded?
AsherBio was founded in 2019.
-
Who is the founder of AsherBio?
Andy Yeung Ph.D and Ivana Djuretic Ph.D are the founders of AsherBio.
-
Who is the CEO of AsherBio?
Craig Gibbs Ph.D is the CEO of AsherBio.
-
Where is AsherBio headquartered?
AsherBio is headquartered in South San Francisco, CA.
-
What is the size of AsherBio?
AsherBio has 36 total employees.
-
What industry is AsherBio in?
AsherBio’s primary industry is Drug Discovery.
-
Is AsherBio a private or public company?
AsherBio is a Private company.
-
What is the current valuation of AsherBio?
The current valuation of AsherBio is .
-
What is AsherBio’s current revenue?
The current revenue for AsherBio is .
-
How much funding has AsherBio raised over time?
AsherBio has raised $218M.
-
Who are AsherBio’s investors?
AstraZeneca, Bristol-Myers Squibb, SNR, Alexandria Venture Investments, and Emles Venture Partners are 5 of 17 investors who have invested in AsherBio.
-
Who are AsherBio’s competitors?
Rakuten Medical, Intensity Therapeutics, Linnaeus Therapeutics, Cellerant Therapeutics, and Monopar Therapeutics are some of the 55 competitors of AsherBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
